Is FTSE 100 Stalwart Smith & Nephew a Good Value?

LONDON -- Capital appreciation is surely the goal of many investors. One method of achieving that is to buy companies with steady earnings growth. If bought when the shares are cheap, two drivers could move the share price up:

  • Growth in earnings.

  • An upward P/E re-rating.

Highly successful fund manager Peter Lynch classified steady growers as Stalwarts, which he typically traded for 20% to 50% share-price gains. But whether buying for gains like that or holding for the longer term, we need to know whether reliable earnings growth can continue, and whether the shares are cheap.

Seeking durable growth
Not all companies achieve stable growth, as you can see by the aggregate performance of those in London's premier FTSE 100 index (UKX), where the compound annual earnings-growth rate has been just 0.7% over the past five years:

Year to June







FTSE 100 index







Aggregate earnings per share







Consistent, cash flow-backed growth in profits is a promising characteristic in today's markets, so, for this series, I'm examining firms with annual earnings growth between 4% and 20%.

One contender is Smith & Nephew (ISE: SN.L) (NYS: SNN) , which manufactures medical devices. This table summarizes the company's recent financial record:

Trading Year






Revenue ($m)






Adjusted earnings per share






So, earnings have grown at an equivalent 9.4% compound annual growth rate, putting the firm in the Stalwart category.

The company supplies joint replacements for knees, hips, and shoulders; the tools for minimally invasive surgery; advanced wound dressings; and the nuts, bolts, plates, and nails used in trauma surgery. Fifty-four percent of revenue comes from orthopedics, 24% from advanced wound management, and 22% from endoscopy. It's a business with a global reach, and Smith & Nephew employs around 11,000 in more than 90 countries.

At the last tally, the U.S. was its biggest market, providing 41% of revenues, followed by Europe, Africa, Asia, and Australasia, providing 33%, and the remaining Americas 26%. The company has been turning these revenues into strong flows of cash to the benefit of the dividend. The recent interim payout was 50% up on the year before.

It's hard to see demand for Smith & Nephew's products waning any time soon, and considering that along with the firm's industry-leading position makes me optimistic about the prospects for continuing earnings growth.

Smith & Nephew's earnings growth and value score
I analyze five indicators to determine whether earnings growth can continue and if the shares offer good value:

1.Growth: Revenue and earnings have been growing; cash flow has been flat. 3/5
2.Level of debt:At the last count, there was net cash on the balance sheet. 5/5
3.Outlook and current trading: We've had good recent trading and a cautiously positive outlook. 4/5
Enterprise value to free cash flow: At around 18, it's above historic growth rates. 1/5
5.Price to earnings: This stands at a trailing 14 and above recent growth rates. 2/5

Overall, I score the firm 15 out of 25, which encourages me to believe this stalwart can continue earnings growth that outpaces that of the wider FTSE 100. When compared with the FTSE's price-to-earnings ratio of around 11 and the firm's growth predictions, the shares seem to price the company fully.

Foolish summary
There has been a good showing on trading and debt reduction, but valuation scores are low, with the company looking expensively priced given its growth expectations.

Right now, forecasted earnings growth is 6% for 2013, and the forward P/E ratio is about 13 with the shares at 651 pence. Considering that and the other factors I've analyzed in this article, I think the firm can stay on watch, for now.

Smith & Nephew is one of several steady-earnings-growing stalwarts on the London stock exchange, each with the potential to deliver significant capital appreciation when purchased at sensible prices.

If you, like me, are serious about capital gains, I recommend you now read "Top Sectors for 2012," in which three Motley Fool Share Advisor analysts each study a favorable industry -- and pinpoint a particular share to consider for this year and beyond.

The report covers various opportunities. One could provide "solid returns and nice dividends," and another offers "global diversification and long-term growth potential," while a third looks at a "high-quality business" from a battered sector.

You can read "Top Sectors for 2012" today by requesting the report free. But hurry, as the report is available for a limited time only.

If you're an ambitious investor hoping to profit from this uncertain economy, as I am, I urge you to read "10 Steps to Making a Million in the Market" today -- it could transform your wealth. Click here now to request your free, no-obligation copy. The Motley Fool is helping Britain invest. Better.

Further investment opportunities:

The article Is FTSE 100 Stalwart Smith & Nephew a Good Value? originally appeared on

Kevin Godbold owns no shares mentioned in this article. The Motley Fool owns shares in Smith & Nephew.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.